Given the beneficial effects of ERRα in skeletal muscle, inhibition of ERRα in the liver or adipose tissue, accompanied by its activation in skeletal muscle would be a therapeutic avenue for the treatment of the metabolic syndrome. This evidence concerns the gene ESRRA and metabolic syndrome.